News

Major update on vaccine for killer virus that could spark next global pandemic
Spread mainly by fruit bats, Nipah virus is fatal in up to 85% of cases. Symptoms include fever, headaches, pain, vomiting ...
KSL1d
Novo's Ozempic linked to rare cases of serious eye disorder, EU regulator says
Novo Nordisk's popular weight-loss and diabetes drugs Wegovy and Ozempic may in very rare cases cause a serious eye condition ...
Pharmaceutical Technology28m
EC approves Alnylam’s vutrisiran for ATTR-CM treatment
The EC has approved Alnylam Pharmaceuticals' Amvuttra (vutrisiran) to treat wild-type or hereditary ATTR-CM in adults.
Devdiscourse1d
Potential Vision Risks Associated with Novo's Weight-Loss Drugs
The European Medicines Agency has indicated that Novo Nordisk's drugs, Ozempic and Wegovy, may rarely cause a serious eye ...
Novo Nordisk's Wegovy Tied To Increased Risk Of Rare Vision-Loss Disorder, European Regulators Say
The European Medicines Agency's (EMA) safety committee (PRAC) has concluded its review of medicines containing semaglutide ...
Tempest Receives Orphan Drug Designation from the European Medicines Agency for Amezalpat for the Treatment of Patients with HCC
EMA Orphan Drug Designation (ODD) builds on U.S. Food & Drug Administration (FDA) ODD and Fast Track Designation, ...
India Today3d
European drugs regulator flags rare eye risk with Ozempic use
The European Medicines Agency has identified a rare eye condition risk linked to Novo Nordisk’s semaglutide drugs.
Dermatology Advisor3d
European Atopic Eczema Guidelines Update Includes New, Expanded Drug Approvals
The latest update atopic dermatitis guidelines include the new approval of lebrikizumab and the expanded use of baricitinib ...
Consilium5d
The pharma package: new EU rules on medicines
The purpose of the pharma package is to revise the current rules on medicines to make them more accessible to patients while ...